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Several reviews of the toxicology of mercury
have appeared recently (1–4). In this present
review I do not repeat all the material pre-
sented in these extensive reviews. Instead I
focus on three chemical species of mercury
that are currently the source of intense
public health interest.
Public health concerns about methyl
mercury in edible tissue of fish suddenly
erupted in 1969 when fish from Lake
St. Clair bordering Michigan were found to
have high levels. This and other ﬁndings dis-
cussed in this review have maintained public
health concerns over this form of mercury.
In 1997, the U.S. Environmental Protection
Agency (U.S. EPA) reduced recommended
safe intakes of methyl mercury by a factor of
about ﬁve (1), which brought public appre-
hension to new heights.
The U.S. EPA-recommended safe intake
level is referred to as the reference dose and
is deﬁned as that dose that can be absorbed
daily for a lifetime without a signiﬁcant risk
of adverse effects. The new reference dose
was estimated in 1997 to be 0.1 µg methyl
mercury/kg body weight/day. This dose
implies that the amount of methyl mercury
ingested in just one 7-oz can of tuna ﬁsh per
week would equal or even slightly exceed the
new limit, depending on the consumer’s
body weight. Other federal regulatory
agency guidelines allow higher levels (4):
The U.S. Food and Drug Administration
(FDA) guideline is equivalent to 0.5 µg
Hg/kg/day, and that of the Agency for Toxic
Substances and Disease Registry (ATSDR) is
0.3 µg Hg/kg/day.
Mercury amalgam tooth fillings have
been used since the early nineteenth century.
Periodically, debates have arisen about the
potential danger from mercury. These
debates are sometimes referred to as the
“amalgam wars.” The most recent began with
an observation in the 1970s that mercury
vapor was released from amalgam, especially
during the process of chewing, and that this
vapor could be inhaled. Concentrations of
mercury vapor measured in the air of the oral
cavity approached and even exceeded occupa-
tional health limits. The debate has now
reached new heights (or lows, depending on
the side of the argument) with claims that
chronic degenerative diseases of the nervous
system such as Parkinson’s disease and
Alzheimer’s disease are caused or exacerbated
by mercury released from amalgam.
In the late summer of 1999, concern was
expressed by the American Academy of
Pediatrics and by the U.S. Public Health
Service about the safety of a mercury preserva-
tive used in many vaccine preparations rou-
tinely administered to infants (5). Within
about 18 months, the mercury preservative
was removed by the manufacturers from all
vaccines destined for use in the United States.
The mercury preservative has the molec-
ular formula CH3CH2–Hg–S–C6H4–
COOH. This preservative was introduced
into vaccines in the early 1930s and has been
used ever since (6). It was given a clean bill
of health by the FDA in 1976 (7). However,
the U.S. EPA later lowered its allowable safe
long-term daily intake for mercury, as dis-
cussed above. As a result, a more recent
review of thimerosal by the FDA raised
questions about possible health risks.
My objective in this review, therefore, is
to give the toxicologic background for these
three species of mercury and the public health
issues surrounding them. In each case, I
address human exposure, disposition in the
body, and adverse effects. Where possible, I
discuss the underlying mechanisms. Emphasis
is on the human target. I also discuss ecologic
aspects only inasmuch as they may play a role
in human exposure.
Quantitative estimates of human health
risks are not made in this review. Such a task
is left to “expert committees” covering a
range of disciplines that cannot be mastered
by one individual. Nevertheless, the toxico-
logic background presented here should give
at least a qualitative idea of the type of health
risks we face from these forms of mercurys.
Methyl Mercury in Fish
History of Human Exposure
The first methyl mercury compounds were
synthesized in a chemical laboratory in
London in the 1860s (8). Two of the labora-
tory technicians died of methyl mercury poi-
soning. This so shocked the chemical
community that methyl mercury com-
pounds were given a wide berth for the rest
of the century. However, early in the twenti-
eth century the potent antifungal properties
of the short-chain alkyl mercury compounds
were discovered, leading to application to
seed grains, especially for cereal crops. The
widespread global use of these mercury com-
pounds was found to be highly protective of
seed grain from what otherwise would be
devastating fungal infections and the loss of
the grain harvest.
Despite this widespread use, few cases of
poisoning were reported for the ﬁrst half of
the twentieth century. However, in the late
1950s and early 1960s serious outbreaks of
alkyl mercury poisoning erupted in several
developing countries (9). The largest, most
recent outbreak occurred in rural Iraq in the
winter of 1971–1972 (10). Some 6,000 cases
were admitted to hospitals. An epidemiologic
follow-up suggested that as many as 40,000
individuals may have been poisoned.
These outbreaks were caused by prepar-
ing homemade bread directly from the
treated seed grain. Several factors con-
tributed to these mass health disasters. The
warning labels were not written in the local
language. Well-known symbols for poisons
in the Western world, such as the skull and
crossbones, have no meaning to rural Arabs
unfamiliar with stories of “pirates on the
Spanish Main.” Typically, a red dye is added
to the treated grain to indicate the presence
of a fungicide. This was counterproductive,
as the victims washed away the dye, thinking
they had also removed the poison. The
insidious properties of methyl mercury were
another important factor, as there is a long
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appearance of symptoms (10).
Also in the late 1950s, evidence emerged
of environmental damage from treated grain
(11). It was observed in Sweden that preda-
tory birds were developing neurologic disor-
ders. These birds were at the top of a food
chain that began with small mammals con-
suming the treated grain freshly planted in
the ﬁelds. Analysis of feathers from museum-
preserved birds indicated a sharp rise in mer-
cury levels at the time when mercurial
compounds were introduced as agricultural
fungicides. Because some of these birds were
migratory, it was possible to show that ele-
vated mercury levels were found only in
those feathers that grew when the birds were
in Sweden.
As a control measure, the Swedish inves-
tigators decided to check mercury levels in
the feathers of ﬁsh-eating birds, where mer-
cury levels were assumed to be low. To their
astonishment, mercury levels were elevated
despite that these birds had no dietary con-
nection with the treated grain. Eventually
this ﬁnding led to a landmark discovery on
the environmental fate of mercury, namely
that microorganisms in the aquatic environ-
ment are capable of converting inorganic
mercury to methyl mercury. This is the ﬁrst
step in the aquatic food chains, where methyl
mercury bioaccumulates in higher organisms
to plankton, herbivorous, and ﬁnally in the
top ﬁsh predators such as sharks and ﬁsh-eat-
ing marine mammals. A similar food chain
exists in bodies of freshwater, with such
species as pike and bass having some of the
highest levels of methyl mercury.
The potential for bioaccumulation in
aquatic food chains was demonstrated dra-
matically in two outbreaks of human poison-
ing in Japan at about this time. The Japanese
health authorities in Minamata had been
aware for some time that ﬁshermen and their
families were suffering from a neurologic dis-
ease, exhibiting signs of incoordination, con-
stricted visual fields, and numbness in the
extremities. The cause was elusive until a vis-
iting physician from Scotland recognized the
neurologic signs and symptoms from cases of
occupational methyl mercury poisoning he
had seen in England in 1939 (8). Eventually
the source in Japan was traced to a factory
manufacturing acetaldehyde, where inor-
ganic compounds of mercury were used as a
catalyst. The producers were unaware that
the synthetic process converted some of the
mercury to methyl mercury, which was dis-
charged into Minamata Bay. It was difﬁcult
to believe that methyl mercury released into
a large ocean bay could be bioaccumulated
to such an extent that the ﬁsh carried levels
of methyl mercury that would prove lethal
when consumed by humans.
Global Cycling of Mercury
The twin discoveries of biomethylation and
bioaccumulation aroused intense interest in
the environmental fate of mercury and in
pathways to human exposure. Methyl mer-
cury was soon detected in all species of ﬁsh
and in fish-consuming animals. The source
appeared to be inorganic mercury biomethy-
lated by microorganisms in sediments of
both fresh and ocean water.
Many anthropogenic sources were iden-
tified. Chloralkali plants discharged inor-
ganic mercury as waste into rivers, lakes, and
ocean bays. Paper pulp factories likewise dis-
charged a variety of mercury compounds
used a slimicides. These practices now have
been eliminated, but contamination of
aquatic sediments now occurs worldwide
because of extensive goldmining operations,
for example, in the Amazon basin (12). 
Large quantities of liquid mercury are
used to extract the sedimentary gold found
in river beds. Pure gold is recovered when
the mercury is evaporated from the amalgam
by heating. It has been estimated that over
130 tons of mercury have been released each
year into the Amazon basin alone (13).
The global cycling of mercury begins
with the evaporation of mercury vapor from
land and sea surfaces. Volcanoes can be an
important natural source (14). The burning
of fossil fuel, especially coal and municipal
waste incineration, is a major anthropogenic
source to the atmosphere. Mercury vapor is a
chemically stable monatomic gas. Its resi-
dence time in the general atmosphere is esti-
mated to be about 1 year. Thus, mercury
vapor is globally distributed even from point
sources. By processes not yet fully under-
stood, the vapor is oxidized in the upper
atmosphere to a water-soluble ionic mercury,
which is returned to the earth’s surface in
rainwater. This global cycling of mercury
results in the distribution of mercury to the
most remote regions of the planet. For
example, environmental mercury levels even
in the arctic water may not differ greatly
from levels in more southern latitudes.
The global cycling of mercury, along
with the processes of biomethylation and
bioaccumulation, implies that humans must
have consumed methyl mercury in ﬁsh dat-
ing back to times before Homo sapiens
evolved (15). It could be argued that environ-
mental levels of mercury vapor were much
higher in an earlier period of the earth’s his-
tory when oxygen had not yet appeared in
the atmosphere. As levels of oxygen began to
rise, increasing amounts of the vapor would
be converted to the ionic form. Life forms at
those Archean times had to protect them-
selves not only from this new toxic gas, oxy-
gen, but also from ionic mercury pouring
down in rainwater. Perhaps it is no coinci-
dence that those proteins and antioxidant
molecules present in today’s cellular machin-
ery to protect against oxygen also are our
main line of defense against mercury.
Disposition in the Body
The U.S. EPA (1,2) and ATSDR (3) in
recent reviews give extensive details on the
disposition of methyl mercury in the body.
A brief review and update are provided here.
About 95% of methyl mercury ingested
in fish is absorbed in the gastrointestinal
tract, although the exact site of absorption is
not known. It is distributed to all tissues in a
process completed in about 30 hr. About 5%
is found in the blood compartment and
about 10% in brain. The concentration in
red blood cells is about 20 times the concen-
tration in plasma. Methyl mercury crosses
the placental barrier. Levels in cord blood are
proportional to but slightly higher than levels
in maternal blood. Levels in the fetal brain
are about 5–7 times that in maternal blood
(16). Brain-to-blood ratios in adult humans
and other primates are approximately in the
same range.
Methyl mercury avidly accumulates in
growing scalp hair. Concentrations in hair
are proportional to simultaneous concentra-
tions in blood but are about 250 times
higher. They are also proportional to con-
centrations in the target tissue, the brain
(16). Longitudinal analysis of strands of
scalp hair can recapitulate past blood and
brain levels (17). Hair and blood are used as
biologic indicator media for methyl mercury
in both the adult and fetal brain (in the lat-
ter case, maternal hair or cord blood).
Methyl mercury is slowly metabolized to
inorganic mercury mainly by microflora in
the intestines, probably at a rate of about 1%
of the body burden per day. Some demethy-
lation also occurs in phagocytic cells The bio-
chemical mechanism is unknown. Although
methyl mercury is the predominant form of
mercury during exposure, inorganic mercury
slowly accumulates and resides for long peri-
ods in the central nervous system. It is
believed to be in an inert form, probably
insoluble mercury selenide (18).
Urinary excretion is negligible, of the
order of 10% or less of total elimination from
the body. Methyl mercury undergoes exten-
sive enterohepatic cycling. It is secreted into
bile and partly reabsorbed into the portal cir-
culation and thereby returned to the liver. A
fraction of the biliary mercury is converted by
microﬂora to inorganic mercury. The latter is
reabsorbed only to a small extent. Thus, most
of the methyl mercury is eliminated from the
body by demethylation and excretion of the
inorganic form in the feces. The processes of
biliary secretion and demethylation by
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The role of these two processes in suckling
human infants is unknown.
The high mobility of methyl mercury in
the body is not due to lipid solubility, as
claimed in some textbooks. Methyl mercury
is present in the body as water-soluble com-
plexes mainly if not exclusively attached to
the sulfur atom of thiol ligands. It enters the
endothelial cells of the blood–brain barrier
as a complex with L-cysteine. The process is
so speciﬁc that the complex with the optical
isomer D-cysteine is not transported.
Structurally, the L-complex is similar to the
large neutral amino acid L-methionine and is
carried across the cell membrane on the large
neutral amino acid carrier (19).
Methyl mercury is pumped out of mam-
malian cells as a complex with reduced glu-
tathione. For example, it is secreted into bile
as a glutathione complex. The glutathione
moiety is degraded in the bile duct and gall
bladder to a dipeptide and finally to the
L-cysteine complex. Presumably, in this form
it is reabsorbed into the bloodstream to be
returned to the liver, thereby completing the
enterohepatic cycle (20–22).
The elimination of methyl mercury
from the body approximates first-order
kinetics. Half-times vary from one tissue to
another but generally fall in the range of
45–70 days. Thus, individuals with long-
term regular exposure to methyl mercury
attain a steady-state body burden in about
1 year (ﬁve half-times).
Several thiol-containing complexing
agents have been successfully used to remove
methyl mercury from the body [e.g., in the
Iraq outbreak; see Clarkson et al. (23)]. An
interesting example is a thiol-containing
resin that, when given by mouth, traps the
methyl mercury secreted in bile and carries it
into the feces. Perhaps the most promising
complexing agent is N-acetylcysteine (24). It
enhances methyl mercury excretion when
given orally, has a low toxicity, and is widely
available in the clinical setting.
Adverse Effects
The major toxic effects of methyl mercury
are on the central nervous system. Its toxic
action on the developing brain differs in
both mechanism and outcome from its
action on the mature organ, so the two
actions are treated separately here [for
detailed reviews, see U.S. EPA and ATSDR
(2,3)]. However, recent reports have raised
the possibility that methyl mercury may
have adverse effects on other targets in
the body.
The mature central nervous system. The
action of methyl mercury on adults is char-
acterized by a latent period between expo-
sure and onset of symptoms. The period can
be several weeks or even months, depending
of the dose and exposure period. Perhaps the
most dramatic example of latency was in the
case of severe, ultimately fatal poisoning of a
chemistry professor from exposure to
dimethyl mercury (25). A single exposure
from a spill of liquid dimethyl mercury took
place in August. The professor continued
her normal professional work without any
apparent ill effects. In November she pre-
sented a paper at an overseas conference. It
was not until late December that the first
symptoms appeared. Within a few weeks the
full syndrome of severe methyl mercury poi-
soning became manifest. Despite many
decades of research on methyl mercury toxi-
cology, the mechanism underlying this long
latent period is still unknown.
Paresthesia, a numbness or a “pins and
needles” sensation, is the first symptom to
appear at the lowest dose (10). This may
progress to cerebellar ataxia, dysarthria, con-
striction of the visual ﬁelds, and loss of hear-
ing. These signs and symptoms are caused
by the loss of neuronal cells in specific
anatomical regions of the brain. For exam-
ple, ataxia results from the loss of the granule
cells in the cerebellum. The neighboring
Purkinje cells are relatively unaffected.
The mechanism underlying the focal
damage to the adult brain is still not estab-
lished with any certainty. Syversen (26)
examined the effect on protein synthesis in
various areas of brain of rats poisoned with
methyl mercury. Protein synthesis was
inhibited in all three areas studied—the
granule and Purkinje cells of the cerebellum,
and the cells from the cortical areas of the
brain. Protein synthesis recovered in two
types of neurons but not in the granule cells.
These data suggest that the focal damage to
the brain is not due to the initial insult but
depends on the capacity of neuronal cells for
repair, as suggested by Jacobs et al. (27).
Apparently the small granule cells lack the
repair systems present in the other larger
cells. Saraﬁan et al. (28) have suggested that
the selective vulnerability of cells in the ner-
vous system may arise from a “critical
absence of inherent protective mechanisms.”
Cellular defenses may be decisive in
determining the toxic outcome and deserve
further study. If we understand the defense
mechanism, we may be able to predict which
individuals are most susceptible. Thiol com-
pounds probably play a key role (29).
Resistant cells have higher levels of the thiol-
containing peptide glutathione (30).
Glutathione also plays a key role in the
excretion of methyl mercury [for further
discussion, see Saraﬁan et al. (28)].
Selenium is a dietary component that
may affect the disposition and toxicity of
methyl mercury. Ganther et al. (31) were the
first to observe that selenium compounds
could delay the onset of toxic effects in ani-
mals fed methyl mercury in tuna. This gave
rise to a series of studies by his group and
others. However, despite promising indica-
tions from animal studies, no deﬁnite studies
have yet been carried out on human popula-
tions co-exposed to methyl mercury and
selenium [for a recent review, see National
Research Council (4)].
Methyl mercury is converted to inor-
ganic mercury in the brain. It is possible that
the inorganic ion is the proximate toxic
agent responsible for the brain damage.
However, experiments on rats comparing
methyl and ethyl mercury compounds sug-
gest that the intact methyl mercury radical is
the toxic agent (32). Ethyl mercury converts
to inorganic mercury more rapidly than
methyl mercury, but the latter produces
more severe brain damage.
Autopsy samples taken years after expo-
sure to methyl mercury reveal that inorganic
species account for most if not all of the
remaining mercury in the brain (33). It has
been suggested that the long residence time
is due to inorganic mercury forming an
insoluble complex with selenium (18).
However, Charleston et al. (34) have chal-
lenged this view, suggesting that inorganic
mercury released in brain tissue from methyl
mercury may be the proximate toxic agent.
The toxicologic role of inorganic mercury
remains a matter of debate.
Other adverse effects in adults. Most epi-
demiologic studies and clinical reports on
adults [for review, see WHO (18)] have
identiﬁed neurologic signs and symptoms of
poisoning associated mainly with the central
nervous system. An important exception is
an extensive study on the relationship
between ﬁsh consumption, levels of mercury
in urine and scalp hair, and risk of cardiovas-
cular disease in adult male residents living in
eastern Finland (35). A statistically signifi-
cant correlation was found between mercury
levels and cardiovascular disease even after
correction for numerous cardiovascular risk
factors. A subsequent study by the same
group found a correlation between mercury
accumulation and accelerated progression of
carotid atherosclerosis (36).
However, it is difficult to draw firm
conclusions. Stress, believed to be a major
risk factor (37), was not directly measured.
The highest recorded hair level of 15.7 ppm
was more than six standard deviations from
the mean. A histogram of hair levels was not
presented, but these statistics imply that a
small percentage of the study group had
high mercury levels. Outlying and “inﬂuen-
tial points” may play a major role in studies
of this type [e.g., Myers et al. (38)]. It
would have been of interest to see if these
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mercury levels were excluded.
Given the serious health implications, a
repeat of this study in another population is
needed. If these ﬁndings are conﬁrmed, two
long-held dogmas may have to be aban-
doned, namely, that methyl mercury primar-
ily affects the central nervous system and
that the prenatal period (see below) is the
most susceptible part of the life cycle.
Effects on the developing brain. The ﬁrst
indication of the special susceptibility of the
developing brain to prenatal exposure to
methyl mercury came from anecdotal reports
from Minamata that mothers with mild
symptoms gave birth to offspring with severe
brain damage. The Iraq outbreak conﬁrmed
that severe brain damage can occur from
high prenatal exposure. A milder syndrome
was also identiﬁed in the Iraq outbreak (39).
Children apparently normal nevertheless had
a history of delayed achievement of develop-
mental milestones and, on examination,
exhibited neurologic abnormalities such as
brisk tendon reflexes. When the prenatal
exposure was determined from mercury lev-
els in maternal hair samples, it was possible
to construct a dose–response relationship
between peak hair mercury levels in preg-
nancy versus number of abnormal offspring
showing developmental delays and abnormal
neurologic ﬁndings (39,40).
This study was of interest for two rea-
sons. First, a dose–response relationship has
been established for prenatal exposures to a
toxicant; that is, a dose to the mother pre-
dicts the probability of effects in her off-
spring. This discovery laid the groundwork
for further quantitative estimate of prenatal
risks from methyl mercury. No doubt this
relationship was made possible by the paral-
lel between levels of mercury in maternal
and fetal tissues. Indeed, it was later demon-
strated in another study that maternal hair
levels of mercury were proportional to levels
in autopsy samples of brain tissue from
infants who died shortly after birth (16).
Ernhart et al. (41), at virtually the same
time, published a dose–response curve for
prenatal exposures to ethanol. Probably as
with methyl mercury, the high mobility of
ethanol ensures that maternal levels predict
those in the fetus.
A second unique aspect of the Iraqi
study (40) was the application of continuous
single-strand hair analysis to determine peak
levels during pregnancy. By the use of X-ray
ﬂuorescence analysis, it was possible to mea-
sure the concentration of mercury in con-
tiguous 2-mm segments of a single strand of
maternal hair, thus giving a complete picture
of mercury levels in pregnancy. Moreover,
because exposure in Iraq took place over a
single period of time, it was possible to fit
the hair data with a single compartment
model covering both the rising levels during
intake and the exponential fall afterward.
This allowed the true peak value to be calcu-
lated from the curve by fitting all the data
points, as opposed to taking the single high-
est value, which would be more prone to
error. It is unfortunate that this method of
analysis was not used in subsequent studies
of prenatal exposure.
The studies of the Iraq outbreak con-
firmed what had been suspected from the
outbreak in Japan, that the fetal brain was
more sensitive than the mature organ. A
Swedish expert group (11) had estimated a
threshold level for neurologic effects in
adults at about 50 ppm in hair, an estimate
conﬁrmed by the ﬁndings in Iraq (10). This
level may be compared with an estimated
threshold as low as 10 ppm for prenatal
effects (milestones of development and neu-
rologic change) in Iraq (40). As these studies
were being conducted and early ﬁndings pre-
sented at scientific meetings, concern arose
that methyl mercury in fish normally con-
sumed in our diet might present risks of pre-
natal damage. Several large epidemiologic
studies were conducted in people consuming
freshwater fish (42) and ocean water fish
(43), and large-scale studies are continuing
even to this day focusing on neuropsycho-
logic development [e.g., (44,45)]. These
studies have not yet provided a consistent
picture of the lowest prenatal levels that offer
a measurable risk of damage to the develop-
ing brain. However, at this time it can be
said that these studies on ﬁsh-eating popula-
tions taken as a whole are consistent with the
original findings in Iraq that effects can be
detected in the range of 10 ppm in maternal
hair. Indeed, a U.S. EPA reference dose pub-
lished recently (2) is identical to the previous
estimate from the Iraq data (1).
Mechanism of prenatal damage. Several
studies have given some insight into the
mechanism underlying prenatal brain dam-
age. Autopsy brain samples from the
Minamata outbreak indicated widespread
damage to all areas of the fetal brain, as
opposed to the focal lesions seen in adult tis-
sue. Microcephaly was also observed (18).
Autopsy tissue from Iraq also gave invaluable
clues to the nature of prenatal brain damage
(46). The normally ordered parallel arrays of
neuronal cells in the cortex were found to be
disrupted, which is indicative of a general
disturbance in the developmental growth of
the brain. Moreover, neurons were present
such as Purkinje cells that had failed to
migrate to the cerebellum. These findings
from both Japan and Iraq indicated that the
most basic processes in brain development
were affected, namely, neuronal cell division
and migration.
Experimental work in animals and
in vitro has provided a mechanism explaining
why methyl mercury inhibits both cell divi-
sion and migration (47–49). These studies
show that the cytoarchitecture ﬁrst affected at
the lowest levels of methyl mercury is the
microtubular system. Intact microtubules are
required for both cell division and migration.
Microtubules are formed by a treadmilling
process whereby assembly from α-and β-
tubulin monomers occurs at one end and dis-
assembly at the other. Apparently, methyl
mercury binds to thiol ligands (–SH) groups
on the tubulin monomers and blocks the
assembly process. The disassembly continues
unchanged, thus leading to the complete loss
of the tubule.
Other adverse effects of prenatal
exposures. Studies in 7-year-old children
revealed an elevation in both systolic and
diastolic blood pressure that correlated with
prenatal exposure to methyl mercury (50).
The study was conducted in the Faroe
Islands on a large cohort of children whose
mothers had ingested methyl mercury
mainly from whale meat but also from ﬁsh.
This effect is seen only at the lower range of
blood levels from about 1 to 10 µg Hg/L.
Above this range no further increase is seen,
even at blood levels in the mother ranging as
high as 250 µg Hg/L.
As elevated blood pressure in children
may be indicative of later cardiovascular prob-
lems, this ﬁnding is of public health concern.
Further work is needed to confirm this
ﬁnding and to understand its mechanism.
Thimerosal in Vaccines
Mercury in the thimerosal molecule is in
the form of ethyl mercury (CH3CH2-Hg+),
for which there is limited toxicologic infor-
mation. Thus, estimates of health risks
from thimerosal in vaccines (7) were based
on the assumption that ethyl mercury is
toxicologically similar to its close chemical
relative, methyl mercury (CH3–Hg+),
about which much is known. However, as
discussed below, there are reasons to believe
that this assumption is not necessarily cor-
rect for all aspects of the disposition and
toxicity of ethyl mercury compounds,
including thimerosal.
History of Human Exposure
Ethyl mercury compounds were ﬁrst synthe-
sized in the nineteenth century in a chemi-
cal laboratory in London (8). In the late
1880s diethyl mercury was ﬁrst used in the
treatment of syphilis, a practice soon aban-
doned because of the toxic properties of this
agent. However, early in the twentieth cen-
tury, the fungicidal properties of the short-
chain alkyl mercury compounds led to
commercial applications in agriculture. For
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plant root disease in wheat caused by
Telletia triticia. In fact, many different
organic mercury compounds were being
used to prevent seed-borne diseases of cereal
by 1914 (51,52).
Generally speaking, the ethyl mercury
fungicides were used effectively and safely.
However, a number of outbreaks of poison-
ing occurred in some developing countries
(8). For example, two outbreaks occurred in
rural Iraq in 1956 and 1960 from the misuse
use of the fungicide ethyl mercury toluene
sulfonilamide (51). The farmers’ families pre-
pared homemade bread directly from the
treated grain instead of planting it. Hundreds
of cases of severe poisoning occurred, many
of which had a fatal outcome. Cases of ethyl
mercury poisoning have occurred in China as
recently as the 1970s. The exposure pathway
was the same as in Iraq: The farmers
consumed rice treated with ethyl mercury
chloride (53).
Ethyl mercury in the form of thimerosal
has found wide application in medicine as a
disinfectant. Axton (54) reported case histo-
ries of four children and two adults severely
poisoned by accidental exposure. Five of the
six cases died. Rohyans et al. (55) reported a
case of severe poisoning from treatment of
an infected ear. Pfab et al. (56) reported on
an attempted suicide from drinking a
solution of thimerosal, resulting in severe
poisoning. Treatment of infants with
omphaloceles resulted in high levels of mer-
cury in autopsy tissues (57). Cases of human
poisoning have also occurred from infusion
of large volumes of plasma containing
thimerosal as a preservative (58,59).
Disposition in the Body
If, after injection of the vaccine, the
thimerosal molecules were to remain intact
for a period sufficient to allow diffusion to
the bloodstream and thence to the kidneys,
rapid excretion might take place. The car-
boxyl group of thiosalicylic acid might allow
thimerosal to be a substrate for the system
responsible for the tubular secretion of weak
acids. Rapid urinary excretion of thimerosal
would then be possible.
This possibility seems unlikely.
Thimerosal contains the ethyl mercury radi-
cal attached to the sulfur atom of the thiol
group of salicylic acid. Generally, mercuric
ions bind tightly but reversibly to thiol lig-
ands (60). It is likely, therefore, that the ethyl
mercury cation will dissociate from the thios-
alicylic acid moiety immediately after injec-
tion to bind to the surrounding thiol ligands
present in great excess in tissue proteins.
Thimerosal is used as a thiol titration
reagent in numerous experimental studies
[e.g., Elferink (61)]. This application would
be possible only if rapid dissociation of ethyl
mercury took place in the presence of
endogenous thiol groups in the cells and tis-
sues under study. In vitro, the thiosalicylate
moiety is degraded by oxidation to dithio-
salicylic acid followed by further oxidation
to 2-sulﬁnobenzoic acid (62).
Ulfvarson (63) demonstrated that the
type of anion attached to the alkyl mercury
radical made little difference to the ultimate
disposition in the body. These include such
anions as hydroxyl, cyanide, and even the
thiol-containing propane diolmercaptide.
These findings suggest that the mercury
radical rapidly dissociates from the anion in
the parent compound to attach to ligands
in tissues. 
Therefore, it is assumed that administra-
tion of thimerosal results in the immediate
release of the ethyl mercury to the surround-
ing tissues. Toxicologically, ethyl mercury in
thimerosal is assumed to follow the same
pathways of disposition as ethyl mercury
absorbed into the body from other ethyl
mercury compounds.
Patterns of tissue disposition and
excretion. Little is known about mercury lev-
els in human tissue after administration of
thimerosal. Suzuki et al. (58) reported levels
of total and inorganic mercury in the tissues
of a 13-year-old boy who had died 5 days
after receiving infusion of artificial human
plasma containing thimerosal as a preserva-
tive. The infusion of plasma had taken place
over a period of 6 months, with a total esti-
mated dose of 284–450 mg Hg. The levels
of total mercury from high to low were in
the following order: liver, kidneys, skin,
brain, spleen, and lowest in plasma. The red
cell levels were at least 10-fold higher than
plasma. The distribution pattern is generally
similar to that seen for methyl mercury.
These findings are supported by studies in
primates dosed with thimerosal (64).
It is interesting that hair levels were
high. The section proximal to the scalp had
a level of 187 µg Hg/g, whereas the level in
blood was approximately 7 µg Hg/mL, giv-
ing a hair-to-blood ratio of 27:1. This is
lower than the commonly assumed ratio for
methyl mercury of 250:1, but possible
redistribution of mercury in autopsy blood
samples and uncertainty in the length and
exact position of the proximal segment
make the estimates of the hair-to-blood
ratio uncertain. However, it does indicate
that ethyl mercury, like methyl mercury, is
accumulated in scalp hair.
Matheson et al. (59) reported on blood
and urine levels in one patient exposed to
thimerosal in long-term injections of gamma
globulin. Speciﬁcally, they reported on levels
of total and inorganic mercury before and
after one injection of gamma globulin. The
data allow a rough calculation of how similar
the observed increase in blood level is to that
expected from methyl mercury. The injected
dose was 0.6 mL/kg containing 50.3 µg
Hg/mL, to give a total mercury dose of 30 µg
Hg/kg. The disposition parameters for
methyl mercury in adult humans (18) predict
that 5% of the dose—1.5 µg Hg—is
deposited in the blood compartment. The
volume of the latter is 70 mL, assuming the
blood compartment is 7% of the body
weight. Thus, 1.5 µg Hg would be deposited
in 70 mL of blood to give an increase on
concentration of 1500/70 µg Hg/L = 21 µg
Hg/L. The observed increase was 18 µg
Hg/L. This calculation suggests that the dis-
position of mercury after thimerosal is not
very different from that expected from
methyl mercury.
The pattern of urinary excretion also
indicates similarities to that with methyl
mercury. Matheson et al. (59) do not quote
a specific figure for the change in urinary
excretion after injection of thimerosal, but
the graph published in their article indicates
little change. They state that 90% of the
total mercury in urine was in the inorganic
form. Adult humans exposed to methyl mer-
cury excrete little mercury in urine and all in
the inorganic form (10).
Conversion to inorganic mercury. There
is, however, one important difference from
methyl mercury illustrated in the report
from Matheson et al. (59). Inorganic mer-
cury accounted for about 50% of the total
mercury in blood samples collected from this
patient. This is in marked distinction from
methyl mercury, where inorganic mercury
accounts for only about 10% of total mercury
in blood (10).
Similar findings were made in the case
described by Suzuki et al. (58). A signiﬁcant
fraction of the total mercury in both gray
and white matter of the brain was in the
form of inorganic mercury of the order of
30–40%. The kidney cortex had the highest
percentage. These ﬁndings are conﬁrmed by
studies on experimental animals (32). Blood
and tissue levels, including the brain, were
higher in animals dosed with ethyl mercury
compared with an equivalent dose of a
methyl mercury compound. The high tissue
levels of inorganic mercury seen in both
humans and animals indicate that ethyl mer-
cury breaks down to inorganic mercury
more rapidly than methyl mercury.
Blood levels from thimerosal in vaccines.
Stajich et al. (65) are the ﬁrst and only investi-
gators to measure disposition of mercury
before and after administration of vaccines
containing thimerosal. They reported on
blood levels of mercury before and 48–72 hr
after administration of a single dose of hepati-
tis vaccine in the ﬁrst week after birth. Seven
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748 g) and five were term infants (average
birth weight, 3,588 g). Prevaccination blood
levels were 0.04–0.5 µg Hg/L. The preterm
infant levels rose to an average value of 7.4 µg
Hg/L, whereas the levels in term infants were
2.2 µg Hg/L.
These levels are similar to those expected
from methyl mercury. The dose was the
same for all infants, 12.5 µg Hg. Five per-
cent, or 0.625 µg Hg, should be deposited in
the blood compartment, which is assumed
to be 8% of the infant’s body weight. Thus,
for the preterm infants, 0.625 µg Hg would
be deposited in a blood volume of 0.08 ×
748 = 60 mL to give a predicted concentra-
tion of 0.625 × 1,000/60 = 10.4 µg Hg/L.
This compares to an observed increase of 6.8
µg Hg/L. The predicted increase for the
term infants based on methyl mercury is
0.625 × 1,000/287 = 2.2. The observed
increase was identical, 2.2 µg Hg/L.
These estimates also suggest that the dis-
position of mercury after a dose of thimerosal
is similar to that expected from methyl mer-
cury. However, these estimates can be
regarded as approximate at best. Individual
values for each infant were not reported. The
blood levels in samples collected between
48 and 72 hr may not have been the true
maximum levels after distribution of the
injected dose.
A preliminary report by Pichichero et al.
(66) indicated blood levels of mercury in
infants lower than what would be expected
from methyl mercury. These infants, ≤6
months of age, had received some vaccines
containing thimerosal. Most blood samples
were collected 1 week or more after the last
vaccination. The highest recorded level was
4.1 µg Hg/L, and many were below the detec-
tion limit of about 0.5 µg Hg/L. When the
authors performed calculations similar to those
described above, they found that the methyl
mercury dispositional parameters predicted
signiﬁcantly higher levels than those observed.
The main difference in design of the
Pichichero et al. (66) study compared with
that of the Stajich et al. (65) study is that in
the former, samples were collected much later
after the last dose of thimerosal. Both studies
could be consistent if the half-time for ethyl
mercury in blood is shorter than that for
methyl mercury. The time after collection of
48–72 hr is too short for a measurable decline
in blood levels in the Stajich et al. study. The
urine levels in the Pichichero et al. study were
low, which is consistent with other observa-
tions on thimerosal discussed previously.
Signiﬁcant amounts of mercury were found
in fecal samples that might account for the
lower blood levels.
In conclusion, both animal and human
studies indicated that the pattern of tissue
disposition of ethyl mercury was qualita-
tively similar to that of methyl mercury, with
brain levels of the intact mercury being
slightly higher for methyl than for ethyl. The
conversion in body tissues to inorganic mer-
cury appears to be substantially faster from
ethyl than from methyl. We know little
about the kinetics of elimination of mercury
from the body when dosed with ethyl mer-
cury compounds. The feces is the main
pathway of elimination. The residence time
in the body is probably shorter for ethyl, but
quantitative data are lacking.
Adverse Effects
Ball et al. (7) have reviewed the animal litera-
ture on ethyl mercury toxicity. Toxicity tests
conducted before marketing thimerosal in
1931 in several animal species involved high
(≤45 mg Hg/kg) acute doses with only a
short follow-up period (67). The studies have
little relevance to today’s concern over risks
from low doses from vaccines. Chronic car-
cinogenicity studies were conducted on rats
with twice weekly doses ranging from 30 to
1,000 µg Hg/kg. Weight loss was observed at
the highest-dose group. Unfortunately, no
brain histopathology was reported, making
these studies difficult to extrapolate to cur-
rent human exposure.
Magos et al. (32) compared the target
organ toxicity of ethyl and methyl mercury
in rats. Five daily doses of 8 mg Hg/kg were
given by gavage for 5 consecutive days. Brain
and kidney histopathology was examined 3
and 10 days after the last dose. In general,
kidney damage was more severe after ethyl
mercury and brain damage more severe after
methyl mercury. However, when the dose of
ethyl mercury was increased by only 20%,
the brain damage was similar or slightly
more severe than that seen from the lower
dose of methyl mercury.
Magos (68) has reviewed the published
cases of human poisoning resulting from
exposure to thimerosal. Severe cases of poi-
soning can result in the same neurologic
signs and symptoms associated with methyl
mercury poisoning, for example, constriction
of the visual ﬁelds. Ethyl mercury poisoning
was characterized by a latent period of sev-
eral weeks between ﬁrst exposure and onset
of the first symptom of poisoning, as has
been observed for methyl mercury. In dis-
tinction from methyl mercury, signs of renal
damage are found in severe cases.
A detailed review of case histories on
exposure to ethyl mercury including
thimerosal allowed Magos (68) to construct
a table comparing blood levels at the time of
onset of symptoms. To estimate such blood
levels from samples collected at a later date,
he assumed a half-time in blood of 50 days.
Severe intoxication was associated with
blood levels in excess of 2,000 µg Hg/L,
with milder intoxication at 1,000 µg Hg/L.
Five cases with blood levels of 140–650 µg
Hg/L had no reported adverse effects. Only
18 cases were involved, with ages ranging
from infants to 79 years. Because of the
small number of individuals, no statistical
evaluation is possible in terms of
dose–response relationships. However, the
data suggest that ethyl mercury is somewhat
less potent in producing neurologic signs
and symptoms than methyl mercury, where
the threshold for neurologic effects has been
estimated at about 200 µg Hg/L (18).
Allergic reactions. Allergic response, usu-
ally by skin application, is well known to
occur from organomercurial compounds,
including thimerosal (69). Santucci et al.
(70) have demonstrated that contact allergy
to thimerosal is due to the ethyl mercury rad-
ical and that it is indistinguishable in its aller-
gic action from methyl mercury. Goncalo et
al. (71) also noted that allergy to thimerosal
was mainly related to the mercurial compo-
nent, but some allergic reactions may be due
to the thiosalicylic acid component.
Allergy to thimerosal and related mer-
cury compounds is a rare event. There is evi-
dence that individuals with certain
polymorphisms in glutathione transferase
genes may be susceptible to allergic reactions
to thimerosal (72). Glutathione is necessary
for the biliary excretion of methyl and inor-
ganic mercury (20), and intracellular glu-
tathione is protective against the toxicity of
methyl mercury (29).
Other effects. Only one case of acrodynia
has been reported from exposure to
thimerosal (59). This occurred in a 20-year-
old man receiving regular gamma globulin
infusions containing thimerosal as a pre-
servative. The total dose was estimated as
40–50 mg Hg.
Acrodynia is now a rare disease. It was
well known to pediatricians when children
were exposed to mercury compounds in
teething powders, vermifuge preparations,
and diaper disinfectants (73). The children
characteristically have pink hands and feet
(hence the alternative name “pink’s dis-
ease”). They are photophobic and suffer
from joint pains. A typical picture is that of
a child with head buried in a pillow and con-
tinually crying. The distraught parents
invariably take the child for medical atten-
tion. Thus, it is unlikely that cases of acrody-
nia would escape attention. It is interesting
that not a single case of acrodynia has been
reported from exposure to vaccines despite
the propensity of thimerosal to produce this
syndrome when given in sufﬁcient amounts.
An important characteristic of the dis-
ease is that only 1 child in 500 exposed chil-
dren develops this disease. The reason for
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ably has a genetic basis. It has made the
identiﬁcation of mercury as the causal agent
very difﬁcult (74).
Although it is unlikely that thimerosal in
vaccines has ever caused acrodynia, the clini-
cal history of this disease gave rise to the idea
that a genetic susceptibility to mercury may
underlie other rare childhood diseases. For
example, Bernard et al. (75) claim that
autism is a “novel form of mercury poison-
ing” that occurs in rare infants who are
genetically susceptible.
In attempts to estimate health risks from
thimerosal in vaccines, a key gap in our
knowledge on the human toxicology of mer-
cury has become apparent. Little is known
about the tissue disposition and toxicity of
mercury in human infants, or in animals for
that matter.
Current health risks from thimerosal in
vaccines depend on the assumption that
ethyl mercury is equally toxic to the nervous
system as methyl mercury. 
For example, Ball et al. (7) quote the U.S.
EPA reference dose as a guide for safe intake
of ethyl mercury. However, this reference
dose is based on data from prenatal exposures
to methyl mercury. In the case of vaccines, we
are dealing with postnatal exposures. The pre-
natal stage is believed to be the window of
highest susceptibility to methyl mercury (18).
Also, evidence reviewed above suggests that
the systemic toxicity of thimerosal is less than
that of methyl mercury compounds.
Dental Amalgam and 
Mercury Vapor
History of Human Exposure
Dental amalgam. Dental amalgam was intro-
duced more than 150 years ago as a tooth ﬁll-
ing restoration. Today it is still the most
popular restorative despite the introduction
of new types of ﬁllings. It is an amalgam of
several metals, but mercury is the principal
component, usually accounting for about
50% by weight. Other metals include silver
and copper. Periodically throughout the his-
tory of dental amalgam, concern has been
expressed about health risks because of the
high content of mercury. These recurrent
concerns have sometimes been referred to as
the “amalgam wars,” reﬂecting the arguments
between the proponents and opponents of
its use. Today we are in the third amalgam
war, which started in the early 1970s and
continues today unabated.
This present war was started by reports
that amalgams released mercury vapor that
could be inhaled. Concentrations of mercury
vapor in the air in the oral cavity were shown
to exceed occupational health standards.
This ﬁnding provoked further investigations
and a series of reviews of potential health
risks from amalgam [e.g., World Health
Organization (76)]. It was soon realized that
comparison with occupational health stan-
dards gave misleadingly high estimates of
health risks. The concentration of mercury
vapor in the oral cavity could indeed reach
occupational health danger levels, but the
quantity of vapor was small because the vol-
ume of the cavity was small. Eventually
more meaningful data have been obtained
indicating that the retained vapor is much
less than that inhaled under conditions of
occupational exposures, except for an inter-
esting exception to be discussed below.
Levels of mercury vapor in the ambient
atmosphere are so low that intake from this
source is negligible. Thus, with the excep-
tion of certain occupational exposures, den-
tal amalgam is the main source of human
exposure to mercury vapor. As discussed fur-
ther below, other forms of mercury released
from amalgam do not appear to be impor-
tant. Thus, a consideration of health risks
from amalgam depends on our knowledge of
the toxicology of inhaled mercury vapor and
the quantities released and inhaled from
amalgam restorations.
Mercury vapor. An important source
book on this topic is Leonard Goldwater’s
Mercury: A History of Quicksilver (77).
Ramazinni’s Diseases of Workers (78), one of
the ﬁrst books on occupational disease, con-
tains fascinating historical details of occupa-
tional exposures to this metal, as does
Donald Hunter’s masterpiece Diseases of
Occupations, last printed some 30 years ago
(8). The most important recent source books
are by the World Health Organization (76),
ATSDR (3), and the U.S. EPA (1,2).
Mercury vapor is a monatomic gas that
evaporates from liquid metallic mercury or is
produced by chemical or physical processes
from chemical compounds of mercury. The
principal ore is cinnabar, a brilliant crimson
crystalline form of mercuric sulfide. The
largest and oldest mine is located in Almaden,
Spain, which has production records dating
back many centuries. These records show
spurts in production as new uses of mercury
were discovered. Perhaps its oldest application
was in the form of cinnabar ﬁrst used by the
Chinese to make red ink for official docu-
ments many centuries before the modern era.
Thus, mercury has the dubious distinction as
the founder of bureaucracy.
In its liquid metallic form, mercury has
found innumerable applications. Spread as a
thin ﬁlm over a sheet of glass, mercury makes
an excellent reflecting surface. An island in
the vicinity of Venice, Italy, is famous for its
mirror makers dating back to the middle
ages. Ramazinni (78) describes the “mirror
makers of Venice” in these terms: 
At Venice on the Island called Murano where
huge mirrors are made, you may see these work-
ers gazing with reluctance and scowling at the
reﬂection of their own sufferings in their mirrors
and cursing the trade they have adopted.
Besides mirror making and gilding, it was
also used in the extraction of gold and silver.
Enormous quantities were shipped for extrac-
tion of gold and silver from Almaden, as well
as from mines in Peru during the Spanish
occupation of Central and South America.
Today, mercury continues to be used in the
largest gold rush of the twentieth century in
the Amazon basin (13). Exposure to mercury
vapor and contamination of local fish also
appears to be occurring at other gold mining
operations around the world (79–81).
Liquid mercury has found important
applications in scientific instruments and
measuring devices. It has found its way into
many homes in thermostats, barometers, and
thermometers. It has been contained in
household gas regulators. Recent attempts by
power companies to replace such meters has
led to spills in the homes because of the care-
less nature by which the meters were
removed. As many as 200,000 homes in the
Chicago, Illinois, area may have been conta-
minated in this way (82).
Perhaps the earliest medical application
may have been in ancient Egypt, where mer-
cury compounds in ointments were used to
treat skin infections. The skin sores from
syphilis may have prompted the early appli-
cation of mercury to combat this disease as it
swept across Europe soon after the return of
Christopher Columbus. Treatment included
not only the application of mercury com-
pounds but also the exposure of the person’s
skin surfaces to mercury vapor. Paracelsus
was one of the first advocates for the mer-
cury treatment, which included skin expo-
sure to the vapor. He soon realized, however,
that a little too much mercury might kill the
patient, hence his famous dictum “Dose
makes the poison.” So it may be argued that
mercury played a key role in establishing the
basic guiding principle in modern toxicology
and risk assessment.
Thus, the signs and symptoms of poison-
ing from inhalation of mercury vapor, at
least in its severe form, have been known for
centuries if not millennia. Severe damage to
the brain, kidneys, and lungs may result,
depending on the length and intensity of
exposure. As discussed below, today’s con-
cerns are with subtle changes in brain and
kidney function associated with occupational
exposure and possibly with amalgam under
certain circumstances. Speculations have
been put forward that inhalation of mercury
vapor from amalgam may be a causative fac-
tor in chronic degenerative diseases of the
brain such as Alzheimer’s disease.
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Mercury vapor. Several recent reviews have
discussed in detail the uptake, distribution,
excretion, metabolism, and kinetics of
inhaled mercury vapor (1,3,76). A brief
summary is presented here with an update
from recent reports.
About 80% of inhaled mercury vapor is
retained in the body. However, approxi-
mately 7–14% is exhaled within a week after
exposure. The half-time of the process is
about 2 days. The dissolved vapor accumu-
lates in red blood cells and is carried to all tis-
sues in the body. It crosses the blood–brain
and placental barriers. The half-time of dis-
tribution to the plasma compartment is
approximately 5 hr (83). The amount of time
to reach a peak value is 9 hr, with a range of
7–24 hr in nine adult subjects. The amount
of mercury in plasma at the time of the peak
concentration was 4% of the inhaled dose
(95% conﬁdence limit, 3–5%). 
Approximately 7% is deposited in the
cranial region after a single exposure to non-
toxic levels of the vapor. The kidney is the
main depository.
Once the vapor has entered the cell, it is
subject to oxidation to divalent inorganic
mercury. The oxidation step is catalyzed
specifically by the enzyme catalase, with
endogenously produced hydrogen peroxide
as the other substrate. The process is inhib-
ited by ethanol. As a result, workers imbib-
ing a moderate amount of an alcoholic drink
retain less of the inhaled vapor. The ﬁnding
that the half-time for exhalation from the
lung is about 2 days suggests that the half-
time for the oxidation in body tissues is
about the same.
Studies with radioactive tracers indicate
that the rate of overall excretion of mercury
from the body can be described by a single
half-time of about 58 days, corresponding to
an excretion rate of slightly more than 1% of
the body burden per day. Most tissues have
the same or shorter half-times. 
The decline in plasma levels of mercury
consists of at least two components: a short
half-time of less than 1 day and a longer one
of about 10 days. Blood levels therefore
reﬂect recent exposure.
Excretion takes place via both urine and
feces. Urinary mercury originates mainly
from mercury in kidney tissue. Urine is the
commonly used biologic marker, as it
reflects the cumulative dose to one of the
main target organs, the kidney. The relation-
ship between urinary excretion and levels in
the other target tissue, the nervous system, is
not well established. As discussed below, uri-
nary mercury levels have been found to show
a rough correlation with signs and symptoms
of damage to the nervous system.
Dental amalgam. Several studies over the
past 30 years or so have demonstrated that
amalgam ﬁlling releases mercury vapor into
the oral cavity. Mouth breathing carries the
vapor to the lung, where it is absorbed and
distributed to tissues, as discussed above.
Mercury levels in autopsy tissue samples,
including the brain, have been shown to cor-
relate with the total number of surfaces of
amalgam restorations. The estimate for the
rate of release in people with amalgam
restoration is 2–17 µg Hg/day (18). The
most recent estimate based on applying phar-
macokinetic parameters to steady-state
plasma levels in people with amalgam sug-
gests an average intake between 5 and 9 µg
Hg/day (83). Kingman et al. (84), in a study
correlating urinary excretion of mercury with
amalgam surfaces, estimated that 10 amal-
gam surfaces would raise urinary levels by 1
µg Hg/L. As discussed below, these are far
below toxic levels. However, excessive chew-
ing, such as occurs when smokers try to stop
smoking by using nicotine-containing chew-
ing gum, may lead to urine levels in excess of
20 µg Hg/g creatinine, thereby approaching
occupational health safe limits (85).
Increased amounts of mercury are
excreted in feces in individuals with amalgam
ﬁllings. Engqvist et al. (86) found that only
25% of the total mercury in fecal samples
was in the form of amalgam particles in sam-
ples taken from six adults with a moderate
load of amalgam fillings. About 80% of an
oral dose of amalgam particles or mercuric
mercury attached to sulfhydryl groups was
excreted in the feces. Interestingly, 60% of an
oral dose of vapor dissolved in water was
retained. Previously it had been assumed that
intake of vapor was due solely to inhalation.
Adverse Effects
Mercury vapor. ACUTE TOXICITY. Cases con-
tinue to occur of severe poisoning and even
fatalities from acute exposure to high levels
of mercury vapor [e.g., see Solis et al. (87)].
Severe lung damage can lead to death from
hypoxia. The poisoning appears to occur in
three phases. The initial phase is character-
ized by flulike symptoms lasting 1–3 days.
The intermediate phase is dominated by
signs and symptoms of severe pulmonary
toxicity. The victim in the final phase will
experience gingivostomatitis, tremor, and
erethism (memory loss, emotional lability,
depression, insomnia, and shyness).
The signs and symptoms of the final
phase are identical to those seen in workers
chronically exposed to mercury levels.
Generally speaking, such cases are rarely seen,
at least in developed countries, where indus-
trial hygiene measures are strictly enforced.
THE NERVOUS SYSTEM. Today, health
concerns are directed toward the risk from
lower levels of exposures. In general, air con-
centrations above 50 µg Hg/m3 in the work-
place, corresponding to steady-state urinary
excretion rates of 60 µg Hg/g creatinine, are
associated with ﬁne tremors in the extremi-
ties that frequently are not noticed by the
worker (76). Slowed nerve conduction veloc-
ity is another preclinical effect found at these
lower levels.
Studies on dentists have suggested
adverse effects at air concentrations lower
that 50 µg Hg/m3 [for review, see Langworth
et al. (88)]. Average air concentrations as low
as 14 µg Hg/m3 were associated with
decreased performance on psychomotor tests.
Changes in mood and behavior have also
been noted, such as emotional lability,
somatosensory irritation, and alterations in
mood scores. As noted by Langworth et al.
(88), such effects may be due to mercury
exposure. An alternative explanation for the
observed correlations is that “dentists with
special personality traits are less careful in the
handling of mercury spills etc. and thus are
more exposed to mercury vapor.” If indeed
these effects result from exposure to mercury,
one should bear in mind that the average lev-
els reported in these studies could be substan-
tially less than peak values that may occur
during installation of the amalgam ﬁllings.
Follow-up studies of workers exposed to
high levels of mercury vapor and no longer
exposed during 10 or more years before being
examined have revealed that adverse effects
may persist on the nervous system.
Mathiesen et al. (89) examined 70 previously
exposed workers (time from last exposure, 1
to 35 years, average 12.7 years). The average
yearly exposure was 8–584 µg Hg/m3. Peak
exposures during any speciﬁc year could have
been much higher than these average levels.
Decreased performance on a number of neu-
ropsychologic tests was found, compared
with a control group of 52 workers. Despite
these high exposure levels, no residual effects
were observed on general intellectual ability
or ability to reason logically.
Workers exposed to high levels of vapor at
some time during 1953–1966 in a nuclear
weapons facility have been the subject of fol-
low-up studies (90,91). Columns of liquid
mercury were used in the separation of
lithium isotopes. The exposure was expressed
as “cumulative average quarterly urine mer-
cury measurements” in units of micrograms
of mercury per liter, from which information
one cannot determine the actual urinary
excretion rate (90). However, according to
comments in the text of this paper (90), mer-
cury workers had urine levels in excess of 600
µg Hg/L. In the more recent study (91), 104
of the surviving workers were compared with
an unexposed group of 201. Residual adverse
effects were found primarily on the peripheral
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effects, as quoted from the authors, “were not
observed for a measure of dementia or other
measures of cognitive function.”
As discussed in the following section on
amalgam, a suggestion has been made that
inhaled vapor originating from amalgam ﬁl-
ings is a cause or predisposing factor to
Alzheimer’s disease (92). The fact that both
these studies (90,91) were unable to detect
any signs or symptoms remotely related to
this disease years after heavy exposure to
mercury vapor argues strongly against this
suggestion. Many of these workers were
exposed for many years to intakes of vapor
more than 100-fold higher than that experi-
enced from amalgam ﬁllings.
No new information on adverse effects
from prenatal exposure has emerged since
previous reviews. However, one study (93)
reported that female squirrel monkeys
exposed during their pregnancy to air con-
centations of 500–1,000 µg Hg/m3 had
blood levels ranging from 25 to 180 µg
Hg/L. No difference was observed between
exposed and nonexposed offspring in various
schedules of reinforcement in terms of lever
pressing and other behavioral measures. The
exposed offspring, however, appeared to vary
more in the test performance. Given the
high levels of prenatal exposure and the min-
imal effects found in the offspring, these
data would suggest that the prenatal period
may not be especially sensitive to the effects
of vapor inhaled by the mother. This is con-
sistent with what is known of the disposition
of inhaled vapor in the maternal–fetal unit.
Although vapor passes across the placenta,
much less accumulates in the fetal brain than
in that of the mother. The fetal liver appears
capable of oxidizing the vapor in its ﬁrst pass
through this organ. The product of oxida-
tion, divalent inorganic mercury, passes the
blood–brain barrier far more slowly than
the vapor.
KIDNEYS. Distinct from the action of
inorganic mercuric compounds, exposure to
mercury vapor does not produce severe kid-
ney damage. However, low-level chronic
exposures at air concentrations above 50 g
Hg/m3 do have adverse effects on the kidney
(94). Decreased selectivity of the glomerular
filter is evidenced by increased excretion of
albumin. Tubular reabsorptive function is
slightly diminished, leading to increased
excretion of low-molecular-weight proteins
such as retinol-binding protein. Damage to
the brush border of the tubular cells is indi-
cated by increased urinary excretion of brush
border antigens. Interstitial effects of mer-
cury result in loss of prostaglandins into the
urine. These biochemical markers detect
effects of mercury well before kidney function
is signiﬁcantly compromised.
Taylor et al. (94) reviewed results from a
wide variety of urinary markers. The results
suggest that mercury, lead, and cadmium
may produce different patterns of changes in
these markers. The most sensitive tests for
the action of mercury are the tubular and
interstitial markers.
MECHANISMS OF TOXICITY. The mecha-
nism of action of inhaled mercury vapor on
brain function is not known. It is assumed
that the vapor is first oxidized to inorganic
divalent mercury that functions as the proxi-
mate toxic agent. The latter can attach to
thiol groups present in most proteins. Thus,
almost any enzyme or structural protein is a
potential target.
As discussed previously, it appears that
the intact mercurial and not its metabolic
product, inorganic mercury, is the proximate
toxic agent in the neurotoxic action of
methyl mercury. Conversely, we assume
divalent inorganic mercury is the proximate
toxic agent after exposure to mercury vapor.
The underlying reason for this apparent con-
ﬂict is not known. Most likely it is because of
the differences in transport and distribution
within the brain. Methyl mercury is trans-
ported as a water-soluble complex that is
metabolized slowly to inorganic mercury
only in phagocytic cells not in neuronal cells.
Mercury vapor diffuses to all parts of the
brain as a lipid-soluble monatomic gas that is
rapidly oxidized to inorganic mercury by the
catalase–hydrogen peroxide pathway present
in all cells.
Pendergrass et al. (92) have presented evi-
dence that inhaled vapor may damage the
microtubular system in brain cells in a man-
ner somewhat similar to that seen for methyl
mercury. They reported that inhaled vapor
can inhibit the binding of guanosine triphos-
phate (GTP) to a β subunit of the tubulin
dimer. The microtubules of neuronal and
other cells are formed from the polymeriza-
tion of tubulin protein subunits in a tread-
milling process such that as one end of the
microtubules is formed, the other end is
being depolymerized (95). GTP binding is
essential for the polymerization step. Thus, if
the formation step is inhibited, the micro-
tubule will disappear as the depolymerization
continues. Microtubules are key cytoskeletal
structures involved in axonal transport, cell
division, and cell migration. It will be inter-
esting to see if exposure to mercury vapor
leads to disappearance of the microtubules, as
has been demonstrated for methyl mercury.
Consistent with action on microtubular
structures, Leong et al. (96) observed that
mercuric ions added in vitro to cultured neu-
rons inhibited outgrowth and disrupted-
membrane structure. Tests with antibodies
for tubulin and actin indicated that the
microtubular structure had disintegrated.
The inhibitory action of methyl mercury
on the assembly of microtubules is well doc-
umented. If further investigation shows that
the microtubule assembly is a common bio-
chemical target for both forms of mercury,
then we face the problem of explaining
why the pathology and clinical signs and
symptoms differ so much.
Understanding the mechanisms of cellu-
lar defenses is just as important as under-
standing the mechanisms of damage.
Thiol-containing molecules probably play a
role in defense as well as being targets for
toxicity. Glutathione complexes with inor-
ganic mercury in liver cells are secreted in
bile and ultimately in the feces. Intracellular
levels of glutathione probably divert mercury
from sensitive sites. The thiol-rich family of
proteins known generically as metalloth-
ioneins also plays a protective role. For
example, metallothionein has been shown to
protect against kidney damage from inor-
ganic mercury (97). More recently, it was
shown that lung damage was more severe in
metallothionein-null mice than in normal
mice after exposure to mercury vapor (98).
Amalgam. Contact hypersensitivity to
mercury is a well-established adverse effect of
amalgam ﬁllings [e.g., see Camisa et al. (99)].
According to these authors, a complete
remission may be expected about 3 months
after the last amalgam ﬁlling is removed.
The existence of other adverse health
effects due to amalgam is presently unknown
but is becoming an area of intensive specula-
tion and controversy. This is partly because
of the limited amount of research on the
safety of amalgam ﬁllings and partly because
of the increased visibility of mercury as a
health risk and stringent regulatory actions
concerning this metal.
Ahlqwist et al. (100) reported on the lat-
est findings of a long-standing study of a
cohort of 1,462 Swedish women established
in 1968–1969. Follow-up studies were con-
ducted in 1974 and 1975, 1980 and 1981,
and in 1992 and 1993. Serum mercury lev-
els correlated with the number of amalgam
ﬁllings. Different clusters of symptoms were
recorded as well as the incidence of diabetes,
myocardial infarction, stroke, and cancer.
No association could be found between
serum mercury levels and disease in this pop-
ulation of middle-aged and older women.
The finding that dental amalgam does
not affect mental health is from two well-
conducted epidemiologic studies—one on
twins in Sweden (101) and the other on
older women, the so-called Nun Study in
the United States (102). The Swedish study
involved approximately 587 subjects from an
on-going Swedish Adoption/Twin Study of
Aging (103). The twin study allowed control
for genetic predisposition to the toxic effects
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gam ﬁllings. No negative effects on physical
or mental health were found. The mean age
of the study group was 66 years.
The study on 129 Catholic nuns aged
75–102 years took advantage of a population
with homogeneous adult life styles and envi-
ronment. No effect of amalgam status
(determined by the number and surface area
of the occlusal surfaces) could be found on
eight different tests of cognitive function.
Cederbrant et al. (104) attempted to
address the possibility that a susceptible
immune system might explain why some
individuals with amalgam ﬁllings claimed to
have psychologic, sensory, or neurologic
symptoms from exposure to mercury. They
used an in vitro lymphocyte proliferation
assay to test for immune sensitivity to inor-
ganic mercury on 23 amalgam patients, 30
healthy blood donors with amalgam, 10
healthy subjects without amalgam, and 9
patients with oral lichen planus (OLP) adja-
cent to the amalgam. In addition to the lym-
phocyte proliferation assay, a wide range of
immune parameters was measured. None of
these end points revealed any signiﬁcant dif-
ference between amalgam patients and con-
trols despite the fact the in vitro assay was
sensitive to the positive control group (OLP).
Because the inhaled mercury vapor is
toxic to the central nervous system,
researchers are now speculating that vapor
from amalgams may be a cause of or an exac-
erbating factor in some well-known degener-
ative diseases such as amyotrophic lateral
sclerosis, Alzheimer’s disease (AD), multiple
sclerosis, and Parkinson’s disease. Speculation
has been most intense concerning AD after a
report that mercury levels were higher in
autopsy brains of AD patients than in brains
of members of a control group (105).
However, subsequent reports have pre-
sented an equivocal picture concerning cor-
relations between tissue levels of mercury
and AD. Fung et al. (106) found no differ-
ence between blood mercury levels or mer-
cury to selenium ratios in AD patients and
controls. All subjects resided in a nursing
home, thus ensuring that environmental and
dietary exposures were similar. Conversely,
Hock et al. (107) found that blood levels in
AD patients were higher than in controls. In
early-onset AD patients, blood levels were 3
times higher than in controls. Blood mer-
cury correlated with concentrations of amy-
loid β peptide on the cerebrospinal ﬂuid in a
subset of these patients. Interestingly, the
increases in blood mercury levels were unre-
lated to the status of dental amalgam. The
reason for the difference in the outcome of
the two studies is not clear, although the
study by Fung et al. (106) may have better
control over exposure to mercury.
Subsequent studies on brain and related
tissues have also discounted a connection
between mercury levels and AD. Fung et al.
(108) found mercury levels were the same in
various anatomical regions of the brain in
AD patients and matched controls. Cornett
et al. (109) found elevated brain levels in
most regions of the brain that were mea-
sured, but no statistical difference could be
established from corresponding mercury lev-
els in control subjects. Mercury levels in
pituitary glands of AD patients were found
to be similar to those of controls (110). In a
study of 56 AD patients and 21 controls,
Saxe et al. (111) found no signiﬁcant associ-
ation of AD with number, surface area, or
history of having dental amalgam restora-
tions. Mercury levels in the brain were the
same in AD and control patients.
Overall studies relating tissue levels of
mercury to AD have not produced a con-
vincing picture of any kind of correlation
with this disease. Even if one were estab-
lished, the “chicken and the egg” issue
would arise: Is mercury the cause of AD or
does AD tissue accumulate mercury more
than normal tissue?
Nevertheless, biochemical studies of
in vitro preparations of nerve cells and of AD
tissue continue to raise a question at least on
a mechanistic basis that the levels of mercury
may in some way be connected with AD.
The brain pathology of AD is characterized
by plaques of amyloid protein and neuroﬁb-
rillary tangles (112). The latter consist of
altered microtubules and microtubule-
associated proteins, especially tau (113) and
are needed for assembly of microtubules from
the tubulin monomers. Phosphorylation of
this protein blocks its ability to promote
microtubule assembly. Mercury can interfere
with the complex process of the treadmilling
of microtubules.
The study by Leong et al. (96) on the
effect of mercury on neurite growth also
noted the appearance of structures resem-
bling neurofibrillary tangles. The study by
Pendergrass et al. (92), noted that mercury
can block the binding of GTP to tubulin,
thus interfering with microtubule assembly.
Other studies have indicated that mercury
can cause hyperphosphorylation of the tau
protein (114).
Oxidative stress has been invoked as a
cause of AD (115,116). Mercury is well
known to cause biochemical changes in cells
is consistent with oxidative stress (114).
Indeed, it has been argued that the same
enzyme system that protects against oxygen
attack also protects against mercury (15).
Such biochemical observations offer tan-
talizing possibilities that mercury can be
involved in a mechanism of AD. The process
of microtubular treadmilling is controlled
largely by thiol-containing proteins. Perhaps
mercury is simply acting as a thiol reagent
and any other thiol-reactive chemical would
produce the same effects. For example, the
lipid peroxidation product 4-hydroxynone-
nal inhibits neurite outgrowth, disrupts neu-
ronal microtubules, and modifies cellular
tubulin. Is this also acting by oxidizing thiol
groups? As yet we do not have a complete
plausible biochemical mechanism for the
genesis of AD, nor do we know how mer-
cury interferes with this process in vitro or
whether or not mercury acts in vivo.
Conclusions and 
Research Needs
The three modern faces of mercury—methyl
mercury in fish, mercury vapor from amal-
gam tooth ﬁllings, and ethyl mercury in vac-
cines—represent our most recent encounter
with this ancient metal. Despite thousands of
years of history of human exposure and
intense research activity in our lifetime, many
of its toxic actions remain unexplained. This
review reveals key gaps in our knowledge,
gaps that highlight important research needs.
The main features of the disposition of
methyl mercury in the body are well known.
Nevertheless, some key gaps remain both in
pharmacokinetics and in the mechanisms of
transport and metabolism.
Fecal excretion is the main pathway of
excretion in adults. Animal data indicate
that this process does not start until the end
of the suckling period. However, we have as
yet no conﬁrmation in human infants. Thus,
we are unable to estimate the cumulative
body burden from methyl mercury known
to be secreted in breast milk. This gap in our
knowledge is especially critical for risk esti-
mates from thimerosal in vaccines.
Demethylation of methyl mercury by
microﬂora in the gut is a key, probably rate-
determining, process in the removal of
methyl mercury from the body. The
microbes involved have not been identified
nor have the biochemical mechanisms of
cleavage of the carbon–mercury bond. The
demethylation process in the gut might well
constitute an important site for interaction
between diet and methyl mercury accumula-
tion in the body. The fiber content of the
diet has already been shown to affect the
excretion rate of mercury (117). The diet
change at the time of weaning may also
affect the activity and composition of the
microﬂora. Further studies in this area might
shed light on why there is such a broad range
of biologic half-times reported for adults
exposed to methyl mercury.
Molecular mechanisms of transport of
mercury across cell membranes have been
identiﬁed, indicating that speciﬁc thiol com-
plexes of methyl mercury can enter cells via
Reviews, 2002 • Clarkson
20 VOLUME 110 | SUPPLEMENT 1 | February 2002 • Environmental Health Perspectivesthe large neutral amino acid carrier and exit
on carriers for glutathione. However, no
studies have reported to date on how methyl
mercury gains entry into the hair follicle and
then concentrates over a hundredfold com-
pared to its concentration in whole blood.
This is an important research priority, as
head hair is the most widely used biologic
indicator for this form of mercury. If the
same entry mechanism operates for hair fol-
licular cells as has been shown for endothe-
lial cells of the blood–brain barrier, then
mercury in hair would represent the species
of mercury in blood that enters the brain.
This would explain why levels in hair have
been shown to parallel levels in brain.
The long latent period between the end
of exposure and the sudden appearance of
symptoms and signs of neurologic damage is
both a fascinating and an insidious property
of the action of methyl mercury on the
mature central nervous system. A slow release
of inorganic mercury might explain this
property if the inorganic form were the prox-
imate toxic species. However, animal experi-
ments indicate that this role is played by the
intact organomercurial moiety. Because the
length of the latent period appears to be
independent of the dose, it is also intriguing
and argues against the accumulation of a
toxic metabolite. It we could determine the
mechanisms underlying the latent period, we
would learn much more about the toxic
action of the “element of mystery.”
Two studies have indicted the possibility
of adverse effects on the cardiovascular sys-
tem both in adults and in prenatally
exposed children. Such effects appear to be
occurring at methyl mercury levels in the
body comparable to those associated with
the lowest levels affecting the central ner-
vous system. There is an urgent need to
conﬁrm these ﬁndings in other populations,
preferably where no co-exposure is occur-
ring to other persistent organic pollutants
such as polychlorinated biphenyls.
Generally, a broad research agenda is
needed to develop the toxicology of
thimerosal, given the paucity of our current
information. Studies should be directed to test
the assumption that the toxicology of
thimerosal is similar to that of methyl mer-
cury, given the fact the current estimates of
human health risks, in particular in infants
receiving vaccines, are based on this assump-
tion. The immediate tissue disposition of mer-
cury following a dose of thimerosal appears to
be both qualitatively and quantitatively similar
to that of methyl mercury, as discussed in this
review. However, such limited evidence as
now exists suggests that the rate of conversion
to inorganic and, subsequently, the rate of
excretion are more rapid, perhaps substantially
so, compared with methyl mercury. Data on
the biologic half-time of the ethyl mercury
radical in body tissues, especially the brain, are
essential for estimates of tissues burdens and
health risk from cumulative exposure from
repeated doses of thimerosal in vaccines given
to infants. Such information needs to be gath-
ered both during and after the suckling period.
Thimerosal also differs from methyl mer-
cury in that it causes kidney damage at about
the same doses that damage the nervous sys-
tem. Experimental evidence indicated that
damage to the nervous system is caused by
the intact organomercurial radical, whether
methyl or ethyl. However, inorganic mer-
cury released from ethyl mercury may be the
proximate toxic agent for kidney damage.
Indeed, the suspected greater rate of release
from ethyl mercury may explain why kidney
damage, if any, occurs only at the later stages
of intoxication from methyl mercury. Thus,
comparative tests of methyl and ethyl mer-
cury should include the renal–cardiovascular
system as well as the nervous system in
developing animals.
It is almost 30 years ago that mercury
vapor was shown to be emitted from dental
amalgam ﬁllings. This led to an outpouring
of numerous articles attempting to measure
the precise amounts of vapor released and of
factors affecting the release rate. In general,
levels of inorganic mercury in tissue caused
by release of vapor from amalgam are well
below those associated with overt toxic effects
or even with subtler neurobehavioral and
renal affects. However, excessive chewing can
raise urine levels close to the lowest safety
limits for occupational exposure to mercury
vapor. Interest is now focused on possible
indirect effects of vapor released from amal-
gam. Despite the fact that several well-con-
ducted epidemiologic studies have indicated
no relationship between dental amalgam and
Alzheimer’s disease, speculation continues
that the small amounts of vapor inhaled from
amalgam may in some as yet unknown way
exacerbate the progress and severity of this
disease. Biochemical studies reviewed in this
article raise intriguing possibilities.
Mechanisms of cellular resistance toward
and defense against these three faces of mer-
cury have received some research attention. It
is suggested that the focal lesions produced in
the adult brain by methyl mercury are the
result not of selective toxic action but of
selective resistance. Those cells having inade-
quate defense mechanisms succumb to the
initial insult. It is likely that intracellular glu-
tathione plays a protective role both in
deﬂecting methyl mercury from sensitive sites
in the cell and by enhancing its exit from the
cell. Other thiol compounds, such as the
metallothioneins, may also play a defensive
role for both inorganic and organic forms of
mercury (118). More detailed biochemical
information of these defense processes should
lead to the identiﬁcation of genes controlling
cellular resistance and thereby give some
genetic insight into host susceptibility.
As we gaze at these three modern faces of
mercury and reflect upon the extensive
research conducted in our lifetime, we must
reluctantly agree with the title of a BBC docu-
mentary broadcast over 25 years ago that this
metal still remains “an element of mystery.”
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